Lung Cancer

Cancer drug development status reported

Published in Vaccine Weekly, January 14th, 2004

Biomira, Inc., (BIOM, BRA) announced plans and milestones for its product pipeline in 2004.

One of the important milestone for 2004 is expected to be the results from the BLP 25 Liposomal vaccine (L-BLP25) phase IIb study of 171 patients with non-small cell lung cancer. The final analysis is expected toward the end of Q1/2004, with results anticipated to be reported shortly thereafter. Biomira will also continue its analysis of data from its phase III Theratope vaccine trial and specifically the subset of women receiving hormonal therapy as part of their initial treatment. The objective here will be to discuss plans with the regulatory authorities, once the strategy has...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-01-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry